«

»

ICARE Newsletter Winter 2019

New Research and Approvals of PARP Inhibitor Drugs to Treat Breast Cancer in BRCA Carriers

image_print

Treatment among patients with advanced or metastatic breast cancer: A PARP inhibitor (talazoparib) was approved by the FDA on October 16, 2018 for BRCA carriers with HER2-negative locally advanced or metastatic breast cancer, based on results of the EMBRACA trial outlined in the last ICARE newsletter.

Litton JK, et al. N Engl J Med. 2018 Aug 23. PMID: 30110579.

Permanent link to this article: https://inheritedcancer.net/1nlw2019/